Simone Mocellin.pdf

Over the last two decades Simone Mocellin has been actively involved in the following main research fields:

1) the role of sentinel node biopsy and radical lymphadenectomy in the therapeutic management of patients with solid tumors (with special regard to melanoma, gastrointestinal cancer and breast cancer);

2) the role of cytoreductive surgery and locoregional treatments  in the therapeutic management of patients with solid tumors (with special regard to in transit melanoma metastases, limb-threatening soft tissue sarcomas, retroperitoneal soft tissue sarcomas, peritoneal carcinomatosis and sarcomatosis, unresectable liver metastases);

3) predictive and prognostic biomarkers for setting up predictive and prognostic models leading to the clinical implementation of nomograms for better patient selection and risk stratification (including the use of tumor specific biomarkers as well as germline single nucleotide polymorphisms, SNP);

4) systematic reviews and meta-analyses (in the field of cancer risk epidemiology and molecular epidemiology, diagnosis, prognosis, therapy, network meta-analysis, dose-response meta-analysis) to support guidelines of evidence based medicine;

5) the role of the immune system in the spontaneous control of tumor growth and as a target for novel immunotherapeutic approaches.

1. Mocellin S, Goldin E, Marchet A, Nitti D. Sentinel node biopsy performance after neoadjuvant chemotherapy in locally advanced breast cancer: A systematic review and meta-analysis. Int J Cancer. 2016 Jan 15;138(2):472-80

2. Benna C, Simioni A, Pasquali S, De Boni D, Rajendran S, Spiro G, Colombo C, Virgone C, DuBois SG, Gronchi A, Rossi CR, Mocellin S. Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. Oncotarget. 2018 Apr 6;9(26):18607-18626

3. Mocellin S, Tropea S, Benna C, Rossi CR. Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies. BMC Med. 2018 Feb 19;16(1):20

4. Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018 Feb 6;2:CD011123

5. Rossi CR, Mocellin S, Campana LG, Borgognoni L, Sestini S, Giudice G, Caracò C, Cordova A, Solari N, Piazzalunga D, Carcoforo P, Quaglino P, Caliendo V, Ribero S; Italian Melanoma Intergroup (IMI). Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study. Ann Surg Oncol. 2018 Jan;25(1):271-279

6. Benna C, Helfrich-Förster C, Rajendran S, Monticelli H, Pilati P, Nitti D, Mocellin S. Genetic variation of clock genes and cancer risk: a field synopsis and meta-analysis. Oncotarget. 2017 Apr 4;8(14):23978-23995

7. Mocellin S, McCulloch P, Kazi H, Gama-Rodrigues JJ, Yuan Y, Nitti D. Extent of lymph node dissection for adenocarcinoma of the stomach. Cochrane Database Syst Rev. 2015 Aug 12;(8):CD001964

8. Mocellin S, Verdi D, Pooley KA, Nitti D. Genetic variation and gastric cancer risk: a field synopsis and meta-analysis. Gut. 2015 Aug;64(8):1209-19

9. Mocellin S, Verdi D, Pooley KA, Landi MT, Egan KM, Baird DM, Prescott J, De Vivo I, Nitti D. Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. J Natl Cancer Inst. 2012 Jun 6;104(11):840-54

10. Mocellin S, Pasquali S, Nitti D. The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins. Ann Surg. 2011 Feb;253(2):238-43

IOV-IRCCS grant “5 per mille” (2017): 50,000 euros